Search research articles
Contact Us
Filters
Showing results (1-10 of 82) with videos related to
Page
of 9
Sort By:
Genome Medicine
|
May 6, 2011
Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
Enrico Derenzini, Anas Younes
Expert Opinion on Investigational Drugs
|
February 28, 2013
Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
Enrico Derenzini, Anas Younes
Journal of Hematology & Oncology
|
June 2, 2018
Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why
Enrico Derenzini, Alessandra Rossi, Davide Treré
Leukemia & Lymphoma
|
June 30, 2025
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events
Enrico Derenzini, Adam Gibb, Michał Kwiatek, et al.
Leukemia & Lymphoma
|
November 5, 2013
Bendamustine: role and evidence in lymphoma therapy, an overview
Enrico Derenzini, Pier Luigi Zinzani, Bruce D Cheson
Anticancer Research
|
September 10, 2014
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment
Patrizia Mondello, Vincenzo Pitini, Carmela Arrigo, et al.
Oncology Reviews
|
February 9, 2026
Ribosome biogenesis rate, a parameter of sensitivity to chemotherapeutic drugs inhibiting rRNA synthesis
Davide Treré, Lorenzo Montanaro, Massimo Derenzini, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 19, 2012
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series
Enrico Derenzini, Beatrice Casadei, Cinzia Pellegrini, et al.
Annals of Hematology
|
October 25, 2025
BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy
Paride Bartolucci, Federica Gigli, Valentina Tabanelli, et al.
Annals of Hematology
|
June 26, 2025
Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma
Alessio Maria Edoardo Maraglino, Simona Sammassimo, Ginevra Lolli, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 82) with videos related to
Sort By:
Page
of 9
Genome Medicine
|
May 6, 2011
Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances
Enrico Derenzini, Anas Younes
Expert Opinion on Investigational Drugs
|
February 28, 2013
Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
Enrico Derenzini, Anas Younes
Journal of Hematology & Oncology
|
June 2, 2018
Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why
Enrico Derenzini, Alessandra Rossi, Davide Treré
Leukemia & Lymphoma
|
June 30, 2025
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events
Enrico Derenzini, Adam Gibb, Michał Kwiatek, et al.
Leukemia & Lymphoma
|
November 5, 2013
Bendamustine: role and evidence in lymphoma therapy, an overview
Enrico Derenzini, Pier Luigi Zinzani, Bruce D Cheson
Anticancer Research
|
September 10, 2014
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment
Patrizia Mondello, Vincenzo Pitini, Carmela Arrigo, et al.
Oncology Reviews
|
February 9, 2026
Ribosome biogenesis rate, a parameter of sensitivity to chemotherapeutic drugs inhibiting rRNA synthesis
Davide Treré, Lorenzo Montanaro, Massimo Derenzini, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 19, 2012
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series
Enrico Derenzini, Beatrice Casadei, Cinzia Pellegrini, et al.
Annals of Hematology
|
October 25, 2025
BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy
Paride Bartolucci, Federica Gigli, Valentina Tabanelli, et al.
Annals of Hematology
|
June 26, 2025
Daratumumab plus bortezomib and dexamethasone as a bridge to allogeneic transplantation in refractory T-cell lymphoblastic lymphoma
Alessio Maria Edoardo Maraglino, Simona Sammassimo, Ginevra Lolli, et al.
Page
of 9